Qunfang Zhou

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Basal Cell Carcinoma

Top Venues

ImmunoTargets and therapy

Journal of hepatocellular carcinoma

Journal of gastroenterology

This page only lists publications with an associated author ORCID identifier.

Publications

Wei Wang, Ruixia Li, Hui Li, Murong Wang, Juncheng Wang, Xiao-Hui Wang, Qunfang Zhou
Addition of Immune Checkpoint Inhibitor Showed Better Efficacy for Infiltrative Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy and Lenvatinib: A Multicenter Retrospective Study. ImmunoTargets and therapy 13 (2024)
Murong Wang, Qunfang Zhou, Hui Li, Mingyu Liu, Ruixia Li, Wei Wang, Xiao-Hui Wang, Jinhua Huang, Feng Duan
Survival Benefit of Lenvatinib Plus PD-1 Inhibitor with or Without HAIC in Advanced Hepatocellular Carcinoma Beyond Oligometastasis: a Multicenter Cohort Study. ImmunoTargets and therapy 13 (2024)
Wei Wang, Ruixia Li, Hui Li, Murong Wang, Juncheng Wang, Xiao-Hui Wang, Qunfang Zhou
Addition of Immune Checkpoint Inhibitor Showed Better Efficacy for Infiltrative Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy and Lenvatinib: A Multicenter Retrospective Study. ImmunoTargets and therapy 13 (2024)
Ruixia Li, Xiao-Hui Wang, Hui Li, Murong Wang, Juncheng Wang, Wei Wang, Qunfang Zhou
Hepatic Arterial Infusion Chemotherapy Combined Lenvatinib and PD-1 Inhibitor Showed Improved Survival for Infiltrative Hepatocellular Carcinoma: A Multicenter Cohort Study. Journal of hepatocellular carcinoma 11 (2024)
Qunfang Zhou, Xiaohui Wang, Ruixia Li, Chenmeng Wang, Juncheng Wang, Xiaoyan Xie, Yali Li, Shaoqiang Li, Xianhai Mao, Ping Liang
Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis. Journal of gastroenterology 57 (9) (2022)